Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Neoplasm Metastasis 1Hematologic Neoplasms 1

Interventions

Cyclophosphamide 2040Radiotherapy 1854Cisplatin 1820Carboplatin 1530Gemcitabine 1432Paclitaxel 1289Bevacizumab 1267Docetaxel 1200pembrolizumab 1196Oxaliplatin 1157Capecitabine 1140Fluorouracil 1059Dexamethasone 971Rituximab 918Nivolumab 908Magnetic Resonance Spectroscopy 858Etoposide 839Doxorubicin 823Drug Therapy 789Radiosurgery 774Irinotecan 774Cytarabine 736fludarabine 714Leucovorin 674Lenalidomide 608fludarabine phosphate 564Temozolomide 552Filgrastim 540Radiation 539Cetuximab 535

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Interventional × Levorphanol × Clear all
NCT03579446 2025-08-03

Levorphanol as a Second Line Opioid in Reducing Pain in Patients With Cancer

M.D. Anderson Cancer Center

Phase EARLY_PHASE1 Terminated
43 enrolled
Other hematologic neoplasm

Neoplasm Metastasis, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡